Mustang Bio Stock Today
| MBIO Stock | USD 0.36 0.01 2.86% |
Performance7 of 100
| Odds Of DistressOver 71
|
Mustang Bio is selling at 0.36 as of the 27th of July 2024; that is 2.86 percent increase since the beginning of the trading day. The stock's open price was 0.35. Mustang Bio has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Mustang Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2024 and ending today, the 27th of July 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of August 2017 | Category Healthcare | Classification Health Care |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. The company has 34.43 M outstanding shares of which 1.27 M shares are now shorted by private and institutional investors with about 0.04 trading days to cover. More on Mustang Bio
Moving against Mustang Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mustang Stock Highlights
| CEO, President | Manuel MD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | IT (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMustang Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mustang Bio's financial leverage. It provides some insight into what part of Mustang Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Mustang Bio (MBIO) is traded on NASDAQ Exchange in USA. It is located in 377 Plantation Street, Worcester, MA, United States, 01605 and employs 80 people. Mustang Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.72 M. Mustang Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.43 M outstanding shares of which 1.27 M shares are now shorted by private and institutional investors with about 0.04 trading days to cover.
Mustang Bio currently holds about 107.37 M in cash with (49.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Mustang Bio Probability Of Bankruptcy
Ownership AllocationMustang Bio secures 8.07 % of its outstanding shares held by insiders and 2.26 % owned by institutional investors.
Check Mustang Ownership Details
Mustang Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Securities, Llc | 2024-03-31 | 10.1 K | |
| Macquarie Group Ltd | 2024-03-31 | 8 K | |
| Tower Research Capital Llc | 2024-03-31 | 8 K | |
| Fmr Inc | 2024-03-31 | 7.3 K | |
| Royal Bank Of Canada | 2024-03-31 | 1.2 K | |
| Nbc Securities Inc | 2024-03-31 | 167 | |
| Wells Fargo & Co | 2024-03-31 | 153 | |
| Advisor Group Holdings, Inc. | 2024-03-31 | 151 | |
| Jpmorgan Chase & Co | 2024-03-31 | 148 | |
| Armistice Capital, Llc | 2024-03-31 | 210 K | |
| Vanguard Group Inc | 2024-03-31 | 205.7 K |
Mustang Bio Historical Income Statement
Mustang Stock Against Markets
Mustang Bio Corporate Management
| Lynn MS | VP Affairs | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Richard MS | Head Development | Profile | |
| Matthew JD | VP Counsel | Profile | |
| Bruce MD | Senior Development | Profile | |
| Peter Carney | Controller Officer | Profile |
Additional Information and Resources on Investing in Mustang Stock
When determining whether Mustang Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mustang Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mustang Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mustang Bio Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.40) | Revenue Per Share (0) | Return On Assets (0.56) | Return On Equity (3.22) |
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.